Answers are grounded in this paper and cite their sources.
Introduction Peri-implantitis is a plaque-associated inflammatory disease characterized by progressive bone loss around implants, yet its underlying molecular mechanisms remain incompletely understood. Although butyric acid, a microbial metabolite enriched in peri-implant lesions, has been implicated in inflammatory tissue destruction, whether it contributes to peri-implantitis through Caspase-3/GSDME-mediated pyroptosis remains unclear. Methods (1) Peri-implant sulcular fluid was collected from healthy implants and peri-implantitis patients. Butyric acid and IL-1β were measured via gas chromatography-mass spectrometry and enzyme-linked immunosorbent assay. (2) Male rats received weekly peri-implant injections of 100 mM sodium butyrate (NaB), with or without the Caspase-3 inhibitor Ac-DEVD-CHO. Inflammation, bone loss, and pyroptosis-related marker expression were evaluated. Results Butyric acid and IL-1β were elevated in peri-implantitis patients and showed a moderate positive correlation (r = 0.6815, P < .05). NaB induced peri-implant inflammation and bone loss as demonstrated by radiographic and histological analyses (BV/TV P < .001; BMD P < .01) with increased Caspase-3 and Gasdermin E (GSDME) expression (immunohistochemical and molecular biological analysis; P < .01). Ac-DEVD-CHO treatment significantly reduced inflammatory cell infiltration, suppressed the expression of pyroptosis-related and osteoclastogenic markers, and attenuated bone loss, as demonstrated by radiographic, histological, and molecular biological analyses. Conclusion NaB exposure was associated with increased Caspase-3/GSDME pathway activation, peri-implant inflammation and bone loss. Caspase-3 inhibition alleviated these pathological changes, supporting this pathway as a potential therapeutic target for peri-implantitis. Clinical relevance Targeting the Caspase-3/GSDME pathway could provide a potential approach for managing peri-implantitis by reducing inflammation and bone loss, offering a possible complement to current treatment strategies.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: